Revolution Medicines' Rasonque improves survival across pancreatic cancer subgroups in Phase 3 trial
RVMD•Revolution Medicines said exploratory Phase 3 RASolute 302 results showed Rasonque improved overall survival versus chemotherapy across evaluated tumor RAS profiles in previously treated metastatic pancreatic cancer, including patients without identified RAS mutations.
1. Subgroup results
Revolution Medicines presented exploratory Phase 3 RASolute 302 subgroup results for Rasonque (daraxonrasib) at ESMO on October 23, 2026. The reported survival benefit persisted across chemotherapy regimens and prior treatment settings, including early metastatic recurrence following perioperative therapy.
